EDGAR Filing Documents for 0001047469-16-014162

Form S-3 - Registration statement under Securities Act of 1933:

SEC Accession No. 0001047469-16-014162

Filing Date

2016-07-06

Accepted

2016-07-05 18:04:29

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	S-3	a2229063zs-3.htm	S-3	443658
2	EX-4.7	a2229063zex-4_7.htm	EX-4.7	541512
3	EX-5.1	a2229063zex-5_1.htm	EX-5.1	27190
4	EX-5.2	a2229063zex-5_2.htm	EX-5.2	19620
5	EX-10.1	a2229063zex-10_1.htm	EX-10.1	213864
6	EX-12.1	a2229063zex-12_1.htm	EX-12.1	49503
7	EX-23.1	a2229063zex-23_1.htm	EX-23.1	4398
8	EX-25.1	a2229063zex-25_1.htm	EX-25.1	137193
9	G142412KII001.JPG	g142412kii001.jpg	GRAPHIC	4864
10	G142412KKI001.GIF	g142412kki001.gif	GRAPHIC	5084
11	G455162.JPG	g455162.jpg	GRAPHIC	13564
	Complete submission text file	0001047469-16-014162.txt		1470840

Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301

Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700

Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)